The lipid lowering efficacy of PCSK9 inhibitors alone vs. statins alone: a meta-analysis.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 41783026 · doi:10.3389/fcvm.2026.1769430
What was done
A systematic review and PRISMA-compliant meta-analysis evaluated the lipid-lowering efficacy of PCSK9 inhibitor (PCSK9i) monotherapy compared with high-intensity statin monotherapy (atorvastatin 40/80 mg daily or rosuvastatin 20/40 mg daily). Eligible studies were RCTs of PCSK9is versus control reporting monotherapy subgroups (predominantly statin-intolerant patients) and RCTs of high-intensity statins versus control. The primary outcome was mean percent change in serum low-density lipoprotein cholesterol (LDL-C). Secondary outcomes included high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), triglycerides (TG), and apolipoprotein B (ApoB).
What was found
Five trials evaluated PCSK9is (n = 766; mean age 57.5 ± 5.1 years; 54.3% women) and 49 trials evaluated statins (n = 19,603; mean age 60.2 ± 2.3 years; 39.9% women). Compared with all high-intensity statin arms combined, PCSK9is demonstrated significantly greater reductions in LDL-C (-52.4% vs. -46.6%, p = 0.03) and ApoB (-43.3% vs. -32.8%, p = 0.004), alongside greater increases in HDL-C (8.0% vs. 4.4%, p = 0.02). In subgroup analyses by specific statin, PCSK9is were superior to atorvastatin and comparable to rosuvastatin for LDL-C, ApoB, HDL-C, and TC, but were inferior to both statins for lowering TG.
Why it matters
As PCSK9 inhibitor patents expire and drug costs decrease, establishing monotherapy efficacy provides evidence on whether these agents could realistically serve as first-line alternatives to high-intensity statins.
Limits
Findings rely on an indirect comparison between separate trial populations rather than direct head-to-head RCTs. The evidence base is heavily skewed in sample size (766 patients in PCSK9i trials vs. 19,603 in statin trials). Baseline characteristics differed between groups, with PCSK9i arms having younger patients, more women, and predominantly statin-intolerant individuals. Clinical cardiovascular endpoints, long-term safety, and adherence were not analyzed.
Cited by
- supports PCSK9 inhibitors are more effective at lowering cholesterol than statins.